Seshu Tyagarajan - 14 Apr 2022 Form 4 Insider Report for Candel Therapeutics, Inc. (CADL)

Role
Chief Technical and Development Officer
Signature
/s/ John Canepa, as Attorney-In-Fact for Seshu Tyagarajan
Issuer symbol
CADL
Transactions as of
14 Apr 2022
Net transactions value
$0
Form type
4
Filing time
15 Apr 2022, 17:05:45 UTC
Next filing
30 Nov 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CADL Stock Option (Right to Buy) Award $0 +120,000 $0.000000 120,000 14 Apr 2022 Common Stock 120,000 $5.19 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares underlying this option shall vest and become exercisable on April 14, 2023, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

Chief Technical and Development Officer